Nuvalent sets out its two-pronged strategy
In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.
Regeneron’s lung cancer Lag3 lag
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
ImmunityBio follows through in lung cancer
A new phase 3 study will test Anktiva in PD-(L)1-relapsed lung cancer.
Affimed needs more time with AFM24
Data deteriorate, leaving cash-strapped Affimed relying on a post-hoc analysis and higher dosing.
More bad vibes kill off Merck’s TIGIT and Lag3
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
